E Hawk

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Can animal models help us select specific compounds for cancer prevention trials?
    Ernest T Hawk
    GI and Other Cancers Research Group, National Cancer Institute, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Recent Results Cancer Res 166:71-87. 2005
  2. ncbi request reprint Biomarkers as surrogates for cancer development
    E Hawk
    DCP GI and Other Cancer Research Group, National Cancer Institute, EPN, Suite 201, 6130 Executive Boulevard, Bethesda, MD 20892 7322, USA
    Curr Oncol Rep 2:242-50. 2000
  3. ncbi request reprint Do statins prevent cancer?
    Ernest T Hawk
    Office of Centers, Training and Resources at the National Cancer Institute, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 3:478-9. 2006
  4. ncbi request reprint Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey
    E Hawk
    Gastrointestinal and Other Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
    Cancer Epidemiol Biomarkers Prev 9:523-7. 2000
  5. ncbi request reprint Celecoxib for the prevention of sporadic colorectal adenomas
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, USA
    N Engl J Med 355:873-84. 2006
  6. ncbi request reprint Colorectal cancer chemoprevention--an overview of the science
    Ernest T Hawk
    Gastrointentinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute NIH, EPN Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Gastroenterology 126:1423-47. 2004
  7. ncbi request reprint Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients
    Frank A Sinicrope
    Department of Gastrointestinal Medicine and Nutrition, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer Epidemiol Biomarkers Prev 13:920-7. 2004
  8. ncbi request reprint Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
    Ernest T Hawk
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892 7317, USA
    Cancer Chemother Biol Response Modif 21:759-89. 2003
  9. ncbi request reprint Prevention and therapy of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Med Clin North Am 89:85-110, viii. 2005
  10. ncbi request reprint Colorectal cancer prevention
    Ernest T Hawk
    GI and Other Cancers Research Group, National Cancer Institute, 6130 Executive Boulevard, Suite 2141, Bethesda, MD 20892 7322, USA
    J Clin Oncol 23:378-91. 2005

Detail Information

Publications35

  1. ncbi request reprint Can animal models help us select specific compounds for cancer prevention trials?
    Ernest T Hawk
    GI and Other Cancers Research Group, National Cancer Institute, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Recent Results Cancer Res 166:71-87. 2005
    ....
  2. ncbi request reprint Biomarkers as surrogates for cancer development
    E Hawk
    DCP GI and Other Cancer Research Group, National Cancer Institute, EPN, Suite 201, 6130 Executive Boulevard, Bethesda, MD 20892 7322, USA
    Curr Oncol Rep 2:242-50. 2000
    ..A step-wise approach to the development of tissue-based biomarkers is presented. These biomarkers may serve as molecular targets for scientific inquiry and intervention, as well as approvable endpoints for clinical trials...
  3. ncbi request reprint Do statins prevent cancer?
    Ernest T Hawk
    Office of Centers, Training and Resources at the National Cancer Institute, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 3:478-9. 2006
  4. ncbi request reprint Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey
    E Hawk
    Gastrointestinal and Other Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
    Cancer Epidemiol Biomarkers Prev 9:523-7. 2000
    ..50 (95% confidence interval, 1.12-2.00) and was similar regardless of the severity of baldness at baseline and was independent of other risk factors, including race and age. MPB seems to be a risk factor for clinical prostate cancer...
  5. ncbi request reprint Celecoxib for the prevention of sporadic colorectal adenomas
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, USA
    N Engl J Med 355:873-84. 2006
    ....
  6. ncbi request reprint Colorectal cancer chemoprevention--an overview of the science
    Ernest T Hawk
    Gastrointentinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute NIH, EPN Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Gastroenterology 126:1423-47. 2004
    ..Innovative research models include the nesting of prevention end points within cancer treatment trials and within trials testing promising preventive compounds intended for nononcologic indications...
  7. ncbi request reprint Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients
    Frank A Sinicrope
    Department of Gastrointestinal Medicine and Nutrition, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer Epidemiol Biomarkers Prev 13:920-7. 2004
    ....
  8. ncbi request reprint Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
    Ernest T Hawk
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892 7317, USA
    Cancer Chemother Biol Response Modif 21:759-89. 2003
  9. ncbi request reprint Prevention and therapy of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Med Clin North Am 89:85-110, viii. 2005
    ..These advances substantiate target-driven approaches to cancer prevention and treatment, and provide fruitful opportunities for future investigations...
  10. ncbi request reprint Colorectal cancer prevention
    Ernest T Hawk
    GI and Other Cancers Research Group, National Cancer Institute, 6130 Executive Boulevard, Suite 2141, Bethesda, MD 20892 7322, USA
    J Clin Oncol 23:378-91. 2005
    ..The threshold for tolerating toxicities is very low in asymptomatic individuals at minimally increased risk for colorectal neoplasia...
  11. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
  12. ncbi request reprint A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer
    Janusz A Jankowski
    Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford University, UK
    Nat Clin Pract Gastroenterol Hepatol 3:101-11. 2006
    ..In this review we systematically assess the evidence for various cancer prevention strategies, especially chemoprevention, and highlight the obstacles to further exploitation of this knowledge base...
  13. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....
  14. ncbi request reprint Serum proteomic profiles suggest celecoxib-modulated targets and response predictors
    Zhen Xiao
    Laboratory of Proteomics and Analytical Technologies and Advanced Biomedical Computing Center, SAIC Frederick Inc, National Cancer Institute at Frederick, Frederick, Maryland, USA
    Cancer Res 64:2904-9. 2004
    ..In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose...
  15. pmc Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
    Asad Umar
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:261-8. 2004
    ....
  16. ncbi request reprint Testing guidelines for hereditary non-polyposis colorectal cancer
    Asad Umar
    Division of Cancer Prevention and Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 4:153-8. 2004
  17. ncbi request reprint The role of cyclooxygenase inhibitors in cancer prevention
    William F Anderson
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Curr Pharm Des 8:1035-62. 2002
    ..Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention...
  18. ncbi request reprint Chemoprevention of colorectal cancer: problems, progress, and prospects
    Jaye L Viner
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Gastroenterol Clin North Am 31:971-99. 2002
    ..The number of trials that are investigating chemopreventives against CR neoplasia is relatively small; if these agents live up to a fraction of their promise, the public health impact may be great (see Table 6)...
  19. ncbi request reprint Chemoprevention of colorectal carcinogenesis
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Int J Clin Oncol 7:2-26. 2002
    ..These targets will help identify more effective and better tolerated preventive agents. Carcinogenesis is now recognized as a disease in itself and has become the target of an ever-expanding array of preventive interventions...
  20. ncbi request reprint Epidemiology and prevention of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Surg Clin North Am 82:905-41. 2002
    ..The challenges and rewards of participation in chemoprevention research--both as patients and health care providers-have never been greater...
  21. ncbi request reprint Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 7322, USA
    Mutat Res 523:137-44. 2003
    ..As newer more specific drugs are developed with few adverse effects this important prevention strategy may become a reality...
  22. ncbi request reprint Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
    Prog Exp Tumor Res 37:210-42. 2003
  23. ncbi request reprint Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers
    Gary J Kelloff
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 12:593-6. 2003
  24. ncbi request reprint Development of COX inhibitors in cancer prevention and therapy
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892 7317, USA
    Am J Clin Oncol 26:S48-57. 2003
    ..Discovering how to apply NSAIDs in persons with-or at risk for-cancer, although challenging, has the potential for considerable clinical and public health benefits...
  25. ncbi request reprint Cyclooxygenase inhibition in cancer prevention and treatment
    William F Anderson
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Expert Opin Pharmacother 4:2193-204. 2003
    ..A brief discussion on the pharmacoeconomic considerations of NSAID and COXIB use and safety issues that have recently been the focus of debate, will be presented...
  26. ncbi request reprint COX-2 in cancer--a player that's defining the rules
    Ernest T Hawk
    J Natl Cancer Inst 94:545-6. 2002
  27. ncbi request reprint Statins in esophageal cancer cell lines: promising lead?
    Ernest T Hawk
    Am J Gastroenterol 103:838-41. 2008
    ....
  28. doi request reprint The Translational Research Working Group developmental pathways: introduction and overview
    Ernest T Hawk
    Office of Centers, Training, and Resources, National Cancer Institute, Rockville, Maryland, USA
    Clin Cancer Res 14:5664-71. 2008
    ..Further development of the pathways is encouraged, as is application of the pathway concept to translational research on other diseases...
  29. pmc Translational Research Working Group developmental pathway for biospecimen-based assessment modalities
    Sudhir Srivastava
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5672-7. 2008
    ..This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway...
  30. ncbi request reprint Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population
    Nina Joshi
    Genetics Branch, Center for Cancer Research, National Cancer Institute NIH, EPS, 6120 Executive Boulevard, Bethesda, MD 20892, USA
    Cancer Res 66:6851-60. 2006
    ..These data suggest that local and systemic immune responses may influence the natural history of esophageal squamous dysplasia...
  31. ncbi request reprint Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population
    Nina Joshi
    Amgen, 1201 Amgen Court West, AW1 J 4144, Seattle, WA 98119 3105, USA
    Cancer Epidemiol Biomarkers Prev 15:1046-7. 2006
    ....
  32. ncbi request reprint Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib
    Paul J Limburg
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 129:863-73. 2005
    ..Squamous dysplasia, the accepted histological precursor for esophageal squamous cell carcinoma, represents a potentially modifiable intermediate end point for chemoprevention trials in high-risk populations...
  33. ncbi request reprint Irreversible ototoxicity associated with difluoromethylornithine
    Christopher D Lao
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, 48109, USA
    Cancer Epidemiol Biomarkers Prev 13:1250-2. 2004
    ..This is the first case reported of irreversible ototoxicity in a clinical trial participant receiving DFMO and, thus, trial participants should be made aware of this small but important risk...
  34. ncbi request reprint Frontiers in cancer prevention research
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 63:5649-55. 2003
  35. doi request reprint The Translational Research Working Group developmental pathway for lifestyle alterations
    Ernest T Hawk
    National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5707-13. 2008
    ..This article discusses key issues associated with the development of lifestyle alterations in light of the pathway...